Mirum Pharmaceuticals Inc Quick Ratio (MIRM) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mirum Pharmaceuticals Inc   (NASDAQ: MIRM)

Mirum Pharmaceuticals Inc 's Quick Ratio

MIRM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.86 below Mirum Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 319 other companies have achieved higher Quick Ratio than Mirum Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1338 to 1653.

Explain Quick Ratio?
How much Cash & cash equivalents MIRM´s has?
What are MIRM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MIRM/financial-strength
https://api.csimarket.com/api/v1/companies/MIRM/fundamentals
https://api.csimarket.com/api/v1/companies/MIRM/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MIRM Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 76.53 %
Y / Y Cash & cash equivalent Change -35.24 %
Quick Ratio MRQ 0.86
MIRM's Total Ranking # 1653
Seq. Current Liabilities Change 27.06 %
Seq. Cash & cash equivalent Change -26.47 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 320
Healthcare Sector # 569
Overall Market # 1653


Quick Ratio Statistics
High Average Low
20.26 5.45 1.42
(Dec 31 2018)   (Mar 31 2026)




Financial Statements
Mirum Pharmaceuticals Inc 's Current Liabilities $ 283 Millions Visit MIRM's Balance sheet
Mirum Pharmaceuticals Inc 's Cash & cash equivalent $ 243 Millions Visit MIRM's Balance sheet
Source of MIRM's Sales Visit MIRM's Sales by Geography


Cumulative Mirum Pharmaceuticals Inc 's Quick Ratio

MIRM's Quick Ratio for the trailling 12 Months

MIRM Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 81.38 %
Y / Y Cash & cash equivalent TTM Growth 34.4 %
Quick Ratio TTM 2.03
Total Ranking TTM # 3887
Seq. Current Liabilities TTM Growth 17.22 %
Seq. Cash & cash equivalent TTM Growth -7.25 %

Quick ratio ranking by company, industry and sector >> Back to MIRM Financial Strength Comparisons >> Go to Compare MIRM Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $283.08 millions, cumulative Quick Ratio decreased to 2.03 below the Mirum Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Mirum Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3739 to 3887.

Explain Quick Ratio?
How much Cash & cash equivalents MIRM´s has?
What are MIRM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 886
Within the Market # 3887


trailing twelve months Quick Ratio Statistics
High Average Low
10.2 2.91 0.62
(Jun 30 2020)   (Jun 30 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Pacira Biosciences inc   2.31 $ 295.577  Millions$ 128.209  Millions
Dogwood Therapeutics inc   2.28 $ 4.948  Millions$ 2.174  Millions
Ardelyx inc   2.23 $ 285.338  Millions$ 127.805  Millions
Schrodinger Inc   2.20 $ 366.358  Millions$ 166.292  Millions
Stoke Therapeutics Inc   2.19 $ 107.271  Millions$ 48.977  Millions
Maravai Lifesciences Holdings Inc   2.14 $ 73.023  Millions$ 34.160  Millions
Ernexa Therapeutics Inc   2.13 $ 5.575  Millions$ 2.614  Millions
Madrigal Pharmaceuticals Inc   2.12 $ 962.387  Millions$ 454.244  Millions
Puma Biotechnology Inc   2.09 $ 108.575  Millions$ 51.971  Millions
Corcept Therapeutics Inc  2.09 $ 370.703  Millions$ 177.675  Millions
Biomea Fusion Inc   2.07 $ 26.403  Millions$ 12.771  Millions
Dianthus Therapeutics Inc   1.95 $ 55.686  Millions$ 28.515  Millions
Xeris Biopharma Holdings Inc   1.95 $ 262.164  Millions$ 134.479  Millions
Ars Pharmaceuticals Inc   1.95 $ 138.354  Millions$ 70.995  Millions
Lite Strategy Inc   1.92 $ 4.281  Millions$ 2.234  Millions
Mineralys Therapeutics Inc   1.91 $ 101.273  Millions$ 53.075  Millions
Amarin Corp Plcuk  1.85 $ 323.379  Millions$ 175.136  Millions
Mustang Bio inc   1.80 $ 14.276  Millions$ 7.947  Millions
Biovie Inc   1.78 $ 7.733  Millions$ 4.350  Millions
Alnylam Pharmaceuticals Inc   1.74 $ 3,587.255  Millions$ 2,063.006  Millions
Mallinckrodt Plc  1.74 $ 1,085.600  Millions$ 624.900  Millions
Insmed Inc  1.73 $ 1,146.626  Millions$ 662.181  Millions
Nkarta Inc   1.72 $ 48.354  Millions$ 28.072  Millions
Mannkind Corporation  1.67 $ 181.525  Millions$ 108.524  Millions
Verastem Inc   1.67 $ 172.801  Millions$ 103.328  Millions
Agios Pharmaceuticals Inc   1.66 $ 128.549  Millions$ 77.588  Millions
Bridgebio Pharma Inc   1.57 $ 1,538.855  Millions$ 977.237  Millions
Arcutis Biotherapeutics Inc   1.51 $ 259.460  Millions$ 172.357  Millions
Regeneron Pharmaceuticals Inc   1.50 $ 9,301.100  Millions$ 6,202.100  Millions
Emergent Biosolutions Inc   1.44 $ 175.700  Millions$ 122.000  Millions

Date modified: 2026-11-04T15:20:59+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.